Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
11/2008
11/13/2008WO2008109365B1 Nucleic acid compounds for inhibiting raf1 gene expression and uses thereof
11/13/2008WO2008100620A3 Bicyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s
11/13/2008WO2008099088A3 Method for the in vitro culture of t cells, in particular t cells infiltrating the so-called til tumours
11/13/2008WO2008099072A3 New 2, 4-dianilinopyrimidines, preparation thereof as drugs, pharmaceutical compositions and use thereof essentially as ikk inhibitors
11/13/2008WO2008097640A8 Triazole compounds that are useful in the treatment of proliferative disorders, such as cancer
11/13/2008WO2008094602A3 1-h-pyrazolo (3,4b) pyrimidine derivatives and their use as modulators of mitotic kinases
11/13/2008WO2008092103A9 Combination cancer treatments comprising elsamitrucin and other agents
11/13/2008WO2008083678A3 Pharmaceutically active compounds
11/13/2008WO2008081331A3 Enhancing the level of antibody expression by framework re-engineering
11/13/2008WO2008079030A8 Methods of immune or haematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer
11/13/2008WO2008078100A3 Tricyclic amine derivatives as protein tyrosine kinase inhibitors
11/13/2008WO2008061020A9 Methods of treating, diagnosing or detecting cancer
11/13/2008WO2008042611A3 Method of using il6 antagonists with mitoxantrone for prostate cancer
11/13/2008WO2008036792A3 Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors
11/13/2008WO2008013631A3 Composition for the enterosorption and management of toxins comprising a calcium aluminosilcilate clay
11/13/2008WO2007145563A8 Benzimidazole derivatives which are to be used as antagonist for the cb1-receptor
11/13/2008WO2007109303A3 Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
11/13/2008US20080280995 Extracts of Latex of Calotropis Procera and to a Method of Preparation Thereof
11/13/2008US20080280987 Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
11/13/2008US20080280967 Antiarthritic agents; antiinflammatory agents; inflammatory bowel disorders; graft verses host disease; antiulcer agents; skin disorders; respiratory system disorders; anticancer agents
11/13/2008US20080280965 Novel tetrahydrocarbazole derivatives having improved biological action and improved solubility as ligands of G-protein coupled receptors (GPCPs)
11/13/2008US20080280957 Heterocyclic Inhibitors of Mek and Methods of Use Thereof
11/13/2008US20080280949 Oxopyridyl Quinoline Amides as Nk3 Receptor Modulators
11/13/2008US20080280937 Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives
11/13/2008US20080280934 Porphyrin ring compound containing cyanovinyl group; reacted with Vilsmeier reagent,complexed with metal ion in prsence of an acid and oxidizer; skin disorders; antiinflammatory agents; anticancer agents; antitumor agents; vascular disorders, vision defects, urogenital system disorders; immunology
11/13/2008US20080280925 Amines as Small Molecule Inhibitors
11/13/2008US20080280920 Plasminogen Activator Inhibitor-1 Inhibitors
11/13/2008US20080280917 Nitrogen-Containing heterocyclyl ketones and methods of use
11/13/2008US20080280910 Phthalazinone derivatives
11/13/2008US20080280909 New phenylalanine derivatives
11/13/2008US20080280906 Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders
11/13/2008US20080280902 Inhibitors of Checkpoint Kinases
11/13/2008US20080280900 Bicyclic pyrimidine derivatives as calcium channel blockers
11/13/2008US20080280899 Cancer; such as 3-({4-[2-(methylthio)-6-phenylpyrido[2,3-d]pyrimidin-7-yl]benzyl}amino)-1-phenylpropan-1-one; serine/threonine kinase (Akt) suppression; increased cellular potency or solubility, greater selectivity, enhanced pharmacokinetic properties, lack of off target activity
11/13/2008US20080280896 Dipyrrole Compounds, Compositions, and Methods For Treating Cancer or Viral Diseases
11/13/2008US20080280891 effective against a broad range of cancers, especially leukemia, non-small cell lung and colon; (6-chloropyridin-3-yl)-[3-hydroxy-5-(1H-indol-4-yl)-phenyl]-methanone; antimitotic agents that can block cell cycle progression
11/13/2008US20080280890 Hydroxylamine compounds and methods of their use
11/13/2008US20080280889 Cancer; N,N-dimethyl-5-phenyl-6-(4-{[4-(5-pyridin-2-yl-1H-pyrazol-3-yl)piperidin-1-yl]methyl}phenyl) pyridazin-3-amine;; serine/threonine kinase (Akt) suppression; increased cellular potency or solubility, enhanced pharmacokinetic properties
11/13/2008US20080280880 Staurosporine Derivatives for Use in Alveolar Rhabdomyosarcoma
11/13/2008US20080280878 Blocking HSP90, particularly ansamycin or 17-allylamino-17-demethoxygeldanamcin; controlling gene expression; tyrosine lkinase inhibitor
11/13/2008US20080280869 Therapy for diseases resulting from mutation of messenger Rna; suppression prenature translation termination; autoimmune diseases; blood disorders; collagen disease; diabetes; neurodegenerative diseases; cardiovascular disorders; central nervous system disorders; antiinflammatory agents
11/13/2008US20080280867 temozolomide and veliparib for prostate cancer
11/13/2008US20080280864 3 beta -hydroxy-17-(1H-imidazole-1-yl)androsta-5,16-diene for treatment of prostate cancer; inhibitor of 17-alpha-hydroxylase/17,20 lyase/17,20 desmolase ( a cytochrome p-450 enzyme )
11/13/2008US20080280859 Gemini vitamin d3 compounds and methods of use thereof
11/13/2008US20080280856 Fibroblast Activation Protein Inhibitor Compounds and Methods
11/13/2008US20080280851 Oral Dosage Forms of Gemcitabine Derivatives
11/13/2008US20080280844 Methods and compositions for the diagnosis and treatment of ewing's sarcoma
11/13/2008US20080280839 Anticancer agent saxifragifolin D, saxifragifolin B
11/13/2008US20080280837 Biologically Active Compounds with Anti-Angiogenic Properties
11/13/2008US20080280834 Compounds and methods for inhibiting apoptosis
11/13/2008US20080280822 Nucleic acid and corresponding protein entitled 161P5C5 useful in treatment and detection of cancer
11/13/2008US20080280821 Polynucleotide encoding the amino acid sequence; DNA sequence which encodes a protein; expression vector gene; cell line; multiple myeloma, leukemia, brain glioma, lung cancer and colon cancer
11/13/2008US20080280813 Complex drug delivery composition and method for treating cancer
11/13/2008US20080280327 Expression vector comprising nucleotide sequences coding bone morphogenic protein/selectin fusion for use in treatment and prvention of inflammatory diseases
11/13/2008US20080280322 Transgenic cell for use as bioreactor in production of human estrogen receptor (HER) specific monoclonal antibody for use in targeted destruction of tumor cells
11/13/2008US20080280308 G protein coupled receptor signaling modulation
11/13/2008US20080279970 Pharmaceutical composition for treating parotid gland tumor, cerebroma and renal cyst
11/13/2008US20080279958 Snake venom compositions and methods of use
11/13/2008US20080279957 Pure extract from bovine bile; stimulant for monocytes and macrophages; in vitro; moderate tumor necrosis factor production; nontoxic to human blood cells; Aids therapy ; anticancer agents; multiple sclerosis; antiarthritic agents; lupus; antidiabetic agents; Crohn's disease; myasthenia gravis
11/13/2008US20080279949 Such as paclitaxel and stabilizer
11/13/2008US20080279932 Vildagliptin salt; in mixture with therapeutic agents such as antidiabetic agents; antilipemic agents; obesity; appetite control; hypotensive agents; cholesterol absorption moderators; anticoagulants; estrogen receptor moderators; transferring across blood-brain barrier
11/13/2008US20080279927 Non-Pegylated Long-Circulating Liposomes
11/13/2008US20080279916 Liposome Preparation
11/13/2008US20080279890 Viral antigens
11/13/2008US20080279887 Recombinant virus encoding an antigen of a disease state; second recombinant virus encoding an immunostimulatory molecule with an exogenous immunostimulatory molecule, chemotherapeutic drug, antibiotic, antiviral drug or antifungal drug.
11/13/2008US20080279870 ALK protein tyrosine kinase, cells and methods embodying and using same
11/13/2008US20080279868 Antibody-Drug Conjugates and Methods of Use
11/13/2008US20080279865 Using cytotoxic t-lymphocyte antigen-4 specific immunoglobulin and anti-androgens as therapeutic tools in treatment of cell proliferative disorders
11/13/2008US20080279860 Using endothelial growth factor specific monoclonal antibody for treatment and prevention of metastatic ovarian cancer; immunotherapy
11/13/2008US20080279857 Therapeutic Agent
11/13/2008US20080279853 TNF-like weak inducer of apoptosis (TWEAK) specific immunoglobulin for use as therapeutic in treatment of pancreatic cell proliferative disorders
11/13/2008US20080279852 Methods of treatment with glycosylated antibodies
11/13/2008US20080279847 Tumor-associated glycoprotein-72 specific immunoglobulin for use in diagnosis, prevention and treatment of cell proliferative disorders
11/13/2008US20080279841 Novel Therapeutic Molecular Variants And Uses Thereof
11/13/2008US20080279823 Modified cytokine for use in tredatment and prevention of autoimmune, cell proliferative targeting and infectious disorders
11/13/2008US20080279822 Crystalline Polymorphs of a CXC-Chemokine Receptor Ligand
11/13/2008US20080279818 Therapeutic mixture comprising antisense agents, chemotherapeutic compounds and bile extract for use in treatment of cell proliferative disorders
11/13/2008US20080279812 Disease Prevention and Vaccination Prior to Thymic Reactivation
11/13/2008US20080279786 Method for Extending Lifespan Delaying the Onset of Age-Related Disease
11/13/2008US20080279785 Novel synthetic agonists of toll-like receptors containing CG dinucleotide modifications
11/13/2008US20080279782 Polymers conjugated with platinum drugs
11/13/2008US20080279774 Perturbed Membrane-Binding Compounds And Methods Of Using The Same
11/13/2008US20080279773 Skeletal-targeted radiation to treat bone-associated pathologies
11/13/2008US20080279764 Method and composition for treating cancer
11/13/2008DE112005003752T5 Neues Pyrrolo[2,1-c][1,4]benzodiapezinhybrid und ein Verfahren zu dessen Herstellung New pyrrolo [2,1-c] [1,4] benzodiapezinhybrid and a process for its preparation
11/13/2008DE102007021862A1 Wässrige pharmazeutische Zubereitung Aqueous pharmaceutical preparation
11/13/2008CA2753209A1 Honokiol analogs and their use in treating cancers
11/13/2008CA2723320A1 Il-12 immunotherapy for cancer
11/13/2008CA2694381A1 Aminopyrimidines useful as kinase inhibitors
11/13/2008CA2688584A1 Aminopyrimidines useful as kinase inhibitors
11/13/2008CA2686638A1 Tnf.alpha. gene expression as a biomarker of sensitivity to antagonists of inhibitor of apoptosis proteins
11/13/2008CA2686382A1 Phenylaminopyrimidine derivatives and compositions thereof as c-kit and pdgfr kinase inhibitors
11/13/2008CA2686379A1 Phenylaminopyrimidine derivatives and compositions thereof as c-kit and pdgfr kinase inhibitors
11/13/2008CA2685954A1 Antibodies binding to an intracellular prl-1 or prl-3 polypeptide
11/13/2008CA2685726A1 Fulvene and fulvalene analogs and their use in treating cancers
11/13/2008CA2685417A1 Viral vector for gene therapy
11/13/2008CA2685389A1 Tricyclic compounds as matrix metalloproteinase inhibitors
11/13/2008CA2685216A1 Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
11/13/2008CA2684922A1 Cytotoxic t cell activator comprising ep4 agonist
11/13/2008CA2684906A1 Cancerous disease modifying antibodies
1 ... 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 ... 2211